Clifford Chance has advised global private equity firm Permira on the acquisition of leading European CNS specialty pharmaceutical company Neuraxpharm through a company backed by the Permira funds, from funds advised by Apax Partners.
Neuraxpharm is one of the fastest growing specialty pharmaceutical companies in Europe with annual revenues in excess of EUR 460 million and 850 employees. The company is focused on the treatment of the central nervous system (CNS), developing and commercializing value-added medicines and consumer healthcare products for chronic patients suffering from neurological and psychiatric disorders including Epilepsy, Parkinson’s, Alzheimer’s, Depression and Psychosis. Neuraxpharm enjoys leading positions in its core markets Germany and Spain, with a #1 position across Europe in many of its more than 115 CNS molecules.
Closing of the transaction is subject to customary closing conditions and is expected in the fourth quarter of 2020.
Permira funds invest in high-growth businesses in resilient end-markets, with longstanding global track-record in successfully transforming market leaders and proven expertise in the healthcare sector. With Neuraxpharm, Permira will support the management’s vision of becoming the leading CNS-focused specialty pharmaceutical platform in Europe through driving the commercialization of the company’s product pipeline and backing its buy-and-build strategy to further expand internationally.
The international Clifford Chance team advising Permira comprised partners Anselm Raddatz (Frankfurt/Düsseldorf), Jörg Rhiel (Frankfurt, both Corporate/Private Equity) and Peter Dieners (Corporate/Healthcare, Düsseldorf), senior associates Maria Röntsch and Nico Basener (both Corporate/Private Equity, Frankfurt), senior associate Carolin Kemmner, associate Ann-Cathrin Bergstedt and of counsel Ulrich Lembeck (all Corporate/Healthcare, Düsseldorf) as well as associates Daniel Gutmann, Friedrich von Bülow and senior associate Gerd Hegele (all Corporate/Private Equity, Frankfurt), associates Marie-Christine Schulte and Matthias Christian Forster (both Düsseldorf) as well as Michael Kümmel (Munich, all Corporate/Private Equity); partner Marc Besen, counsel Dimitri Slobodenjuk, senior associate Caroline Scholke and associate Anna Maurer (all Competition, Düsseldorf), counsel Florian Reiling (IP, Düsseldorf) as well as partner Stefan Simon and counsel Christopher Fischer (both Employment, Frankfurt). From the firm’s London office, a team around partner Spencer Baylin, director Martin Kolmar and senior associate Victoria Ho (all Corporate/Private Equity), and from the Madrid and Barcelona offices a team around partners Samir Azzouzi Maanan and Guillermo Guardia, counsel Carme Briera Dalmau and associates Sonia Sebe Marin, Jorge Daniel Garcia Juarez and Patricia Puertas Diaz were involved.
The post Clifford Chance advises Permira on the acquisition of Neuraxpharm appeared first on Legal Desire.
Clifford Chance advises Permira on the acquisition of Neuraxpharm published first on https://immigrationlawyerto.tumblr.com/
Mary Mosley 